CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis.
about
Applications of CYP450 testing in the clinical settingClopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice?Application of routine electronic health record databases for pharmacogenetic researchInfluence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysisPharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumonClinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementationImpact of CYP2C9, VKORC1 and CYP4F2 genetic polymorphisms on maintenance warfarin dosage in Han-Chinese patients: A systematic review and meta-analysisInterethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individualsCYP2C9 genotype vs. metabolic phenotype for individual drug dosing--a correlation analysis using flurbiprofen as probe drugPrognosis research strategy (PROGRESS) 4: stratified medicine researchCharacterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population.Warfarin anticoagulant therapy: a Southern Italy pharmacogenetics-based dosing model.Association of CYP2C9 Genetic Variants with Vitiligo.Validation and comparison of pharmacogenetics-based warfarin dosing algorithms for application of pharmacogenetic testingA novel, single algorithm approach to predict acenocoumarol dose based on CYP2C9 and VKORC1 allele variants.Prevalence of combinatorial CYP2C9 and VKORC1 genotypes in Puerto Ricans: implications for warfarin management in Hispanics.Pharmacogenetic association study of warfarin safety endpoints in Puerto RicansGenotyping three SNPs affecting warfarin drug response by isothermal real-time HDA assays.Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial.Pharmacogenetics of warfarin in a paediatric population: time in therapeutic range, initial and stable dosing and adverse effects.Warfarin dosage response related pharmacogenetics in Chinese population.Pharmacogenomics: application to the management of cardiovascular diseaseAssociation of warfarin dose with genes involved in its action and metabolism.Warfarin dose requirement in Turkish patients: the influences of patient characteristics and polymorphisms in CYP2C9, VKORC1 and factor VIIEvaluation of genetic factors for warfarin dose predictionPrevalence of Warfarin Genotype Polymorphisms in Patients with Mechanical Circulatory Support.A Novel Admixture-Based Pharmacogenetic Approach to Refine Warfarin Dosing in Caribbean Hispanics.Pharmacogenomic testing: relevance in medical practice: why drugs work in some patients but not in others.Impact of genetic factors (VKORC1, CYP2C9, CYP4F2 and EPHX1) on the anticoagulation response to fluindione.Overview of antiviral and anti-inflammatory treatment for severe acute respiratory syndrome.A novel algorithm for analyzing drug-drug interactions from MEDLINE literature.Analysis of genetic variations in CYP2C9, CYP2C19, CYP2D6 and CYP3A5 genes using oligonucleotide microarrayRole of cytochrome P450 genotype in the steps toward personalized drug therapy.Pharmacogenomics: from bedside to clinical practice.Heuristic methods for finding pathogenic variants in gene coding sequences.Contribution of CYP2C9 to variability in vitamin K antagonist metabolism.Pharmacogenetics of warfarin: current status and future challenges.A critical appraisal of the scientific basis of commercial genomic profiles used to assess health risks and personalize health interventionsRole of pharmacogenomics in the management of traditional and novel oral anticoagulantsDosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans
P2860
Q24621760-C6E29996-A64C-4A3A-8859-9FB0B7A054D2Q26823542-7F46BA55-4558-45C0-A355-631E2C6435E4Q26864747-1C3729FA-9A59-4700-B812-06998FE83DBFQ27002899-C3D06851-F236-4389-B839-9544A4691096Q27006860-2784F112-8BD8-4A39-87C3-F3AE5C1228BDQ27011524-5AA8FC83-23AA-427E-920C-371E1731D1BDQ28071310-CF1F0F47-FCAE-4D4E-AD76-0B7F3678905AQ28237144-65C5A8EF-0919-4AD8-A000-5F9809FEED86Q28544111-A42C743C-6052-4A76-9A6D-B45E52B921A6Q28709167-21C67E3E-94C5-4E0A-876B-6BECEE9EEC53Q30939373-F21B12AE-DDEC-46C9-A700-BB80BD9957EFQ31131437-4E2B9ABD-E5F5-463D-BEF2-AEE9A43E681EQ33801991-B2BA6FAA-A67A-4B63-99D4-DD7A3EF44B53Q33813830-580CE2D3-6668-41BC-BF0D-A19B40CB98C3Q33921846-0076DA30-8C58-4A2A-9D8D-C55BE4367502Q33990441-A89B9DF2-A4F3-493A-95CF-342499D53D4CQ34337948-95C0C00E-F481-4AA5-B582-2D95A89764F6Q34348637-D2F848D7-569E-4C6F-9964-EE7701AD0132Q34397841-7DEE0B08-87A3-4830-8D20-AE6FC6D862CBQ34402967-CB93EB99-058B-4107-A383-B5124590F322Q34977531-323DB3FC-CB78-4382-88E4-5A001CFD915AQ35309161-C8861CAC-871B-4FF4-899D-45E6A0DD8E02Q35633802-CB2A337D-57A5-4EED-8B3D-E5600E955819Q35678294-C66A838A-3857-441E-8280-D86FCD8878D0Q35758421-E8501064-3B06-4326-9391-54B514CFE1DEQ35806323-08B04925-84D1-430C-8AA2-C8A473C8CC8EQ35888757-4CF44CCE-001D-4767-A3D4-8BE182A9627AQ35955515-449066CD-7785-466E-AED1-0E787616D34BQ36017389-3DB71E31-8072-4922-AAEE-D9EF749F1BECQ36140676-100BA0A1-5D03-4E43-B6BB-DCEBB9FDDBBAQ36323871-B8666B1F-317B-4782-851F-2AA5318F9FBCQ36412046-87D2F0B7-7C16-4FBB-993E-2A762F985B82Q36441521-91CDF29A-272F-460D-8F1F-96621A586271Q36465177-EE228A25-8AE5-4B7A-8E7D-A9E34E0BE0C4Q36522616-01545C5B-D9DB-4375-B6FC-F585EC2D7C31Q36545011-A8C40950-8169-4E22-B593-8F5B9F2945E8Q36597343-7F4366D7-ABB9-4DCF-83D5-6D452BECD56EQ36719129-2C4ED5E2-3AA1-407F-89F2-01E3DAF878AFQ36848449-FDC62AAB-CAC6-444C-822C-18F4A310196EQ36882317-7B1D2A07-DDE8-4CAF-B3BA-638405D1EE4D
P2860
CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis.
description
2005 nî lūn-bûn
@nan
2005 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
CYP2C9 gene variants, drug dos ...... atic review and meta-analysis.
@ast
CYP2C9 gene variants, drug dos ...... atic review and meta-analysis.
@en
CYP2C9 gene variants, drug dos ...... atic review and meta-analysis.
@nl
type
label
CYP2C9 gene variants, drug dos ...... atic review and meta-analysis.
@ast
CYP2C9 gene variants, drug dos ...... atic review and meta-analysis.
@en
CYP2C9 gene variants, drug dos ...... atic review and meta-analysis.
@nl
prefLabel
CYP2C9 gene variants, drug dos ...... atic review and meta-analysis.
@ast
CYP2C9 gene variants, drug dos ...... atic review and meta-analysis.
@en
CYP2C9 gene variants, drug dos ...... atic review and meta-analysis.
@nl
P2860
P1433
P1476
CYP2C9 gene variants, drug dos ...... atic review and meta-analysis.
@en
P2093
Simon Sanderson
P2860
P304
P356
10.1097/01.GIM.0000153664.65759.CF
P407
P577
2005-02-01T00:00:00Z
P6179
1015756339